|
1
|
Plataniotis G and Castiglione M: ESMO
Guidelines Working Group: Endometrial cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21:(Suppl 5). v41–v45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weiderpass E, Persson I, Adami HO,
Magnusson C, Lindgren A and Baron JA: Body size in different
periods of life, diabetes mellitus, hypertension, and risk of
postmenopausal endometrial cancer (Sweden). Cancer Causes Control.
11:185–192. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yasa C, Takmaz O, Dural O and Akhan SE:
The value of tumor markers in endometrial carcinoma: Review of
literature. J Cancer Ther. 4:966–970. 2013. View Article : Google Scholar
|
|
6
|
Dudley B, Brand RE, Thull D, Bahary N,
Nikiforova MN and Pai RK: Germline MLH1 mutations are frequently
Identified in Lynch Syndrome patients withcolorectal and
endometrial carcinoma demonstrating isolated loss of PMS2
immunohistochemical expression. Am J Surg Pathol. 39:1114–1120.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vasen HF, Stormorken A, Menko FH,
Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P and
Wijnen JT: MSH2 mutation carriers are at higher risk of cancer than
MLH1 mutation carriers: A study of hereditary nonpolyposis
colorectal cancer families. J Clin Oncol. 19:4074–4080.
2001.PubMed/NCBI
|
|
8
|
Basil JB, Swisher EM, Herzog TJ, Rader JS,
Elbendary A, Mutch DG and Goodfellow PJ: Mutational analysis of the
PMS2 gene in sporadic endometrial cancers with microsatellite
instability. Gynecol Oncol. 74:395–399. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Devlin LA, Graham CA, Price JH and
Morrison PJ: Germline MSH6 mutations are more prevalent in
endometrial cancer patient cohorts than hereditary non polyposis
colorectal cancer cohorts. Ulster Med J. 77:25–30. 2008.PubMed/NCBI
|
|
10
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Albitar L, Carter MB, Davies S and Leslie
KK: Consequences of the loss of p53, RB1, and PTEN: Relationship to
gefitinib resistance in endometrial cancer. Gynecol Oncol.
106:94–104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swisher EM, Peiffer-Schneider S, Mutch DG,
Herzog TJ, Rader JS, Elbendary A and Goodfellow PJ: Differences in
patterns of TP53 and KRAS2 mutations in a large series of
endometrial carcinomas with or without microsatellite instability.
Cancer. 85:119–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Senol S, Sayar I, Ceyran AB, Ibiloglu I,
Akalin I, Firat U, Kosemetin D, Engin ZP and Aydin A: Stromal clues
in endometrial carcinoma: Loss of expression of beta-catenin,
epithelial-mesenchymal transition regulators, and
estrogen-progesterone receptor. Int J Gynecol Pathol. 35:238–248.
2015. View Article : Google Scholar
|
|
14
|
Kafshdooz T, Ardabili SM Mohaddes,
Kafshdooz L, Tabrizi AD, Ghojazadeh M, Gharesouran J and Akbarzadeh
A: C-kit mutations in endometrial cancer: Correlation with tumor
histologic type. Asian Pac J Cancer Prev. 16:7449–7452. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zighelboim I, Schmidt AP, Gao F, Thaker
PH, Powell MA, Rader JS, Gibb RK, Mutch DG and Goodfellow PJ: ATR
mutation in endometrioid endometrial cancer is associated with poor
clinical outcomes. J Clin Oncol. 27:3091–3096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang G, Lu X and Yuan L: LncRNA: A link
between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv M, Xu P, Wu Y, Huang L, Li W, Lv S, Wu
X, Zeng X, Shen R, Jia X, et al: LncRNAs as new biomarkers to
differentiate triple negative breast cancer from non-triple
negative breast cancer. Oncotarget. 7:13047–13059. 2016.PubMed/NCBI
|
|
18
|
Herriges MJ, Swarr DT, Morley MP, Rathi
KS, Peng T, Stewart KM and Morrisey EE: Long noncoding RNAs are
spatially correlated with transcription factors and regulate lung
development. Genes Dev. 28:1363–1379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo Q, Cheng Y, Liang T, He Y, Ren C, Sun
L and Zhang G: Comprehensive analysis of lncRNA-mRNA co-expression
patterns identifies immune-associated lncRNA biomarkers in ovarian
cancer malignant progression. Sci Rep. 5:176832015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhai W, Li X, Wu S, Zhang Y, Pang H and
Chen W: Microarray expression profile of lncRNAs and the
upregulated ASLNC04080 lncRNA in human endometrial carcinoma. Int J
Oncol. 46:2125–2137. 2015.PubMed/NCBI
|
|
21
|
Singh H and Aplin JD: Adhesion molecules
in endometrial epithelium: Tissue integrity and embryo
implantation. J Anat. 215:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Avizienyte E, Wyke AW, Jones RJ, McLean
GW, Westhoff MA, Brunton VG and Frame MC: Src-induced de-regulation
of E-cadherin in colon cancer cells requires integrin signalling.
Nat Cell Biol. 4:632–638. 2002.PubMed/NCBI
|
|
23
|
Park JH, Lee BI, Song ES, Whang SO, Lee WY
and Cho SJ: Hypermethylation of E-cadherin in endometrial
carcinoma. J Gynecol Oncol. 19:241–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hecht JL, Dolinski BM, Gardner HA,
Violette SM and Weinreb PH: Overexpression of the alphavbeta6
integrin in endometrial cancer. Appl Immunohistochem Mol Morphol.
16:543–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kulasingam V, Zheng Y, Soosaipillai A,
Leon AE, Gion M and Diamandis EP: Activated leukocyte cell adhesion
molecule: A novel biomarker for breast cancer. Int J Cancer.
125:9–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stuart JM, Segal E, Koller D and Kim SK: A
gene-coexpression network for global discovery of conserved genetic
modules. Science. 302:249–255. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Birney E, Stamatoyannopoulos JA, Dutta A,
Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis
ET, Thurman RE, et al: Childrens Hospital Oakland Research
Institute: Identification and analysis of functional elements in 1%
of the human genome by the ENCODE pilot project. Nature.
447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Congrains A, Kamide K, Oguro R, Yasuda O,
Miyata K, Yamamoto E, Kawai T, Kusunoki H, Yamamoto H, Takeya Y, et
al: Genetic variants at the 9p21 locus contribute to
atherosclerosis through modulation of ANRIL and CDKN2A/B.
Atherosclerosis. 220:449–455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson R: Long non-coding RNAs in
Huntingtons disease neurodegeneration. Neurobiol Dis. 46:245–254.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan SX, Wang J, Yang F, Tao QF, Zhang J,
Wang LL, Yang Y, Liu H, Wang ZG, et al: Long noncoding RNA DANCR
increases stemness features of hepatocellular carcinoma by
derepression of CTNNB1. Hepatology. 63:499–511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kumarswamy R, Bauters C, Volkmann I, Maury
F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F and Thum
T: Circulating long noncoding RNA, LIPCAR, predicts survival in
patients with heart failure. Circ Res. 114:1569–1575. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lei B, Xu SP, Liang XS, Li YW, Zhang JF,
Zhang GQ and Pang D: Long non-coding RNA MVIH is associated with
poor prognosis and malignant biological behavior in breast cancer.
Tumour Biol. 37:5257–5264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang CH, Qiu J, OSullivan D, Buck MD,
Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ,
et al: Metabolic competition in the tumor microenvironment is a
driver of cancer progression. Cell. 162:1229–1241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raccosta L, Fontana R, Corna G, Maggioni
D, Moresco M and Russo V: Cholesterol metabolites and tumor
microenvironment: The road towards clinical translation. Cancer
Immunol Immunother. 65:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji J, Shu X, Li X, Sundquist K, Sundquist
J and Hemminki K: Cancer risk in hospitalised asthma patients. Br J
Cancer. 100:829–833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roncarolo F and Infante-Rivard C: Asthma
and risk of brain cancer in children. Cancer Causes Control.
23:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
